Drug Profile
Research programme: monoclonal antibody therapeutics - BioWa/CSL
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator CSL
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Australia
- 09 Oct 2008 Early research in undefined indication in Australia